This Article Full Text Full Text (PDF) All Versions of this Article: 118/16/1643    most recent CIRCULATIONAHA.108.778811v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by Pitt, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack Hazardous Substances DB POTASSIUM SPIRONOLACTONE Related Collections Cardio-renal physiology/pathophysiology Cardiovascular Pharmacology Related Article

(Circulation. 2008;118:1643-1650.)
© 2008 American Heart Association, Inc.

Heart Failure

Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)

Bertram Pitt, MD; George Bakris, MD; Luis M. Ruilope, MD; Lorenzo DiCarlo, MD; Robin Mukherjee, PhD, on Behalf of the EPHESUS Investigators

From the University of Michigan School of Medicine (B.P.), Ann Arbor; University of Chicago (G.B.), Pritzker School of Medicine, Chicago, Ill; Complutense University (L.M.R.), Madrid, Spain; and Pfizer Inc (L.D., R.M.), New York, NY.

Correspondence to Bertram Pitt, MD, University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109. E-mail bpitt{at}med.umich.edu

Received March 11, 2008; accepted July 9, 2008.

Background— Aldosterone blockade is recommended for patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction; however, the perceived risk of hyperkalemia may limit implementation of this therapeutic approach. This subanalysis examined the relationship between eplerenone, serum potassium (K⁺), and clinical outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

Methods and Results— Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction 40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313). Patients were excluded if baseline K⁺ was >5.0 mEq/L or serum creatinine was >2.5 mg/dL. In patients receiving standard therapy, the addition of eplerenone resulted in a 4.4% absolute increase in the incidence of K⁺ >5.5 mEq/L, a 1.6% increase of K⁺ 6.0 mEq/L, and a 4.7% absolute decrease in hypokalemia (K⁺ <3.5 mEq/L). Four independent baseline predictors of hyperkalemia (defined as 6.0 mEq/L) were identified: potassium (K⁺ greater than the median; 4.3 mEq/L), estimated glomerular filtration rate (60 mL · min^–1 · 1.73 m^–2), history of diabetes mellitus, and prior use of antiarrhythmic agents. None of these independent baseline risk factors significantly impacted the cardiovascular benefit of eplerenone for reducing all-cause mortality.

Conclusions— Use of selective aldosterone blockade with eplerenone within the dose range of 25 to 50 mg/d in post–acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction who are treated with standard therapy improves outcomes without an excess of risk of hyperkalemia (6.0 mEq/L) when periodic monitoring of serum K⁺ is instituted.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 1605-1606. [Extract] [Full Text]

This article has been cited by other articles:

				B. Pitt RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice Heart, August 1, 2009; 95(15): 1205 - 1208. [Full Text] [PDF]

				A. Desai Hyperkalemia Associated With Inhibitors of the Renin-Angiotensin-Aldosterone System: Balancing Risk and Benefit Circulation, October 14, 2008; 118(16): 1609 - 1611. [Full Text] [PDF]